The CiPA initiative – How it will change the way we do drug development in the future

The CiPA initiative – How it will change the way we do drug development in the future

Symposia at the 2015 Annual Meeting of the Safety Pharmacology Society (SPS)

Praque, Czech Republic, Sept 29, 2015

Title: CiPA – The four letter word that may revolutionize in vitro cardiac safety testing.

BernardFermini

By Bernard Fermini. Ph.D.

  • CiPA Steering commitee board member 
  • Chairman CiPA Ion Channel Working Group
  • Ion Channel Discipline Lead Global Safety Pharmacology
    at Pfizer Groton, Connecticut, USA


 

Title: Evolving Market Needs in Safety screening: beyond hERG and CiPA

SimonHebeisen By Simon Hebeisen. Ph.D.
  • Chief Scientific Officer B’SYS, Witterswil, Switzerland

 

 

Title: Using high quality HTS automated patch clamp data from human cardiac ion channels and in silico action potential modelling to cost–effectively predict QT prolongation and arrhythmia risk for CiPA

MarcRogers

By Marc Rogers. Ph.D.

  • Chief Scientific Officer Metrion Bioscience, Cambridge, United Kingdom